Effect of Xuebijing Injection （血必净注射液） on Systemic Lupus Erythematosus in Mice
Objective： To observe the effects of Xuebijing Injection （血必净注射液） on dendritic cells （DCs） and T lymphocytes, and the potential mechanisms of its therapeutic effect on systemic lupus erythematosus （SLE）. Methods： A widely used mouse model, SLE-prone BLLF1 mice aged 8-10 weeks, was employed. Mice wer...
Saved in:
| Published in: | 中国结合医学杂志：英文版 no. 9; pp. 675 - 682 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective： To observe the effects of Xuebijing Injection （血必净注射液） on dendritic cells （DCs） and T lymphocytes, and the potential mechanisms of its therapeutic effect on systemic lupus erythematosus （SLE）. Methods： A widely used mouse model, SLE-prone BLLF1 mice aged 8-10 weeks, was employed. Mice were randomly divided into 4 groups： a normal group, a model group and two treatment groups treated with Xuebijing Injection with a dose of 6.4 mL/kg via intraperitoneal administration for SLE-prone BLLF1 mice aged 8 weeks （treatment A group） and 10 weeks （treatment B group）. Renal tissue sections were stained with Masson＇s trichrome and periodic acid-silver methenamine. Histopathological changes in the kidney were evaluated by a light microscopy. The capacity of the DCs isolated from the spleen to stimulate the T cell proliferation in response to concanavalin A （Con A） was determined. Results： Compared with the model group, levels of anti-dsDNA antibodies in the two treatment groups decreased remarkablely （P〈0.01, P〈0.05）, and levels of serum creatinine and blood urea nitrogen increased （P〈0.01, P〈0.05）. Pathological changes were found in the kidney in the model group. Histopathological abnormalities were alleviated in the two treatment groups. Treatment with Xuebijing injection also significantly upregulated the expression of CD80, CD86 and major histocompatibility class Ⅱ by DCs compared with the model group （P〈0.05）. When splenic T lymphocytes from BLLF1 mice were co-cultured with DCs at ratios of 1：100, 1：150 and 1：200 for 3 and 5 days, the proliferation of T lymphocytes was suppressed compared with the normal group （P〈0.05）, but this was restored by Xuebijing Injection under the same conditions. In the model group, levels of tumor necrosis factor （TNF）-α in supernatants were significantly elevated compared with the normal group （P〈0.01）, interleukin-2 levels decreased （P〈0.05）, while these changes were significantly alleviated in the Xuebijing treatment groups. Conclusions： Xuebijing Injection alleviated renal injury in SLE-prone BLLF-1 mice. The mechanism might be through influencing T cell polarization mediated by DCs, and Xuebijing Injection might be a potential drug that suppresses immune dysfunction in patients with SLE. |
|---|---|
| Bibliography: | WANG Yan-bo, WANG Qiang , YAO Yong-ming , SHENG Zhi-yong and LIU Yu-feng （ 1. Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi＇an （710032）, China; 2. Chinese Center for Disease Control and Prevention, Beijing （102206）, China; 3. Burns Institute, First Hospital Affiliated to the Chinese PLA General Hospital, Beijing （100048）, China ） Xuebijing Injection, systemic lupus erythematosus, lupus nephritis, dendritic cell, T lymphocyte, cytokine, proliferative response, mice 11-4928/R Objective： To observe the effects of Xuebijing Injection （血必净注射液） on dendritic cells （DCs） and T lymphocytes, and the potential mechanisms of its therapeutic effect on systemic lupus erythematosus （SLE）. Methods： A widely used mouse model, SLE-prone BLLF1 mice aged 8-10 weeks, was employed. Mice were randomly divided into 4 groups： a normal group, a model group and two treatment groups treated with Xuebijing Injection with a dose of 6.4 mL/kg via intraperitoneal administration for SLE-prone BLLF1 mice aged 8 weeks （treatment A group） and 10 weeks （treatment B group）. Renal tissue sections were stained with Masson＇s trichrome and periodic acid-silver methenamine. Histopathological changes in the kidney were evaluated by a light microscopy. The capacity of the DCs isolated from the spleen to stimulate the T cell proliferation in response to concanavalin A （Con A） was determined. Results： Compared with the model group, levels of anti-dsDNA antibodies in the two treatment groups decreased remarkablely （P〈0.01, P〈0.05）, and levels of serum creatinine and blood urea nitrogen increased （P〈0.01, P〈0.05）. Pathological changes were found in the kidney in the model group. Histopathological abnormalities were alleviated in the two treatment groups. Treatment with Xuebijing injection also significantly upregulated the expression of CD80, CD86 and major histocompatibility class Ⅱ by DCs compared with the model group （P〈0.05）. When splenic T lymphocytes from BLLF1 mice were co-cultured with DCs at ratios of 1：100, 1：150 and 1：200 for 3 and 5 days, the proliferation of T lymphocytes was suppressed compared with the normal group （P〈0.05）, but this was restored by Xuebijing Injection under the same conditions. In the model group, levels of tumor necrosis factor （TNF）-α in supernatants were significantly elevated compared with the normal group （P〈0.01）, interleukin-2 levels decreased （P〈0.05）, while these changes were significantly alleviated in the Xuebijing treatment groups. Conclusions： Xuebijing Injection alleviated renal injury in SLE-prone BLLF-1 mice. The mechanism might be through influencing T cell polarization mediated by DCs, and Xuebijing Injection might be a potential drug that suppresses immune dysfunction in patients with SLE. |
| ISSN: | 1672-0415 1993-0402 |